Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

NCT03847519 is registered in ClinicalTrials.gov with Advaxis, Inc. as lead sponsor.

NCT NCT03847519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03847519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer
Lead sponsor
Advaxis, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 12, 2019
Completion date
February 22, 2022
Enrollment
24 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non-small cell, metastatic non-squamous cell carcinoma, metastatic squamous cell carcinoma